LDS/Medical Tests/EarlyTect® Bladder Cancer Detection Test (PENK Gene Methylation Assay)

EarlyTect® Bladder Cancer Detection Test (PENK Gene Methylation Assay)

Bladder cancer (BC) ranked 10th of most commonly diagnosed worldwide and 4th of most commonly diagnosed in men in the US based on the data in 2021 annual report. The overall 5-year survival rate is 77% between 2011-2017 (Cancer.org), but the survival rate dramatically changes depending on the stage of BC when it was detected and started to be treated. While the survival rate is around 96% at in situ alone stage, more than 15% of the rate is significantly dropped by the increase of staging at the initial diagnosis. Therefore, early detection of BC is critical to improving the patient’s survival rate.

The most common presenting symptom of BC is blood in the urine, also called “hematuria” which accounts for around 80% to 90% of patients diagnosed with BC. However, hematuria can be caused by benign reasons such as urinary tract or kidney infections, and, bladder or kidney stones, and so on. It is critical to identify and differentiate individuals with BC from those with hematuria in order to provide effective treatment and increase survival rates.

Abnormal DNA methylation is a major mechanism for inactivating tumor suppressor genes and other cancer-related genes in a variety of cancers. It has been also identified as one of the most common molecular changes in BC, with the potential to be used as a promising diagnostic biomarker.

The EarlyTect® BCD is an in vitro diagnostic device designed to detect the presence of BC by analyzing urine DNA for hematuria patients through qualitative analysis of a single epigenetic biomarker gene (PENK) DNA methylation (mePENK). The EarlyTect® BCD is for use with a real-time, quantitative methylation-specific PCR (qMSP) detection system coupled with linear target enrichment (LTE) step. The PENK biomarker and related technologies for mePENK-LTE-qMSP have been granted US patents for the diagnosis and surveillance of bladder cancer.

The EarlyTect® BCD is indicated for use by qualified healthcare professionals as a non-invasive, quick method as aid to detect or rule out bladder cancer from patients with hematuria in conjunction with cystoscopy and cytology. The test is provided by Promis Diagnostic Laboratories and more information can be found at: https://www.promisdx.com.

  • To detect or rule out bladder cancer from patients with hematuria in conjunction with cystoscopy and cytology
  • As an aid in the diagnosis and management of bladder cancer

Positive

  • A positive for PENK methylation would indicate that CpG island of PENK gene is methylated, which might be development of bladder cancer or bladder cancer recurrence. Also, it might be diagnostic of upper urinary tract cancer.

Negative

  • A negative would indicate the absence of bladder cancer or bladder cancer might exist below the limit of detection of the assay, which does not rule it out.

Negative for PENK methylation (no cancer present)

One step of innovative linear target enrichment (LTE) & quantitative methylation-specific real-time PCR (qMSP) technology (mePENK-LTE-qMSP) in a closed single tube.

Fresh voided urine in in proprietary urine collection kit.

Stability Ambient: 30 days.

Urinalysis, Urine cytology, bladder biopsy, bladder cytology by FISH (UroVysion), FGFR3, NMP22.
1-4 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login